Assessment of Cardiometabolic Risk

The new approach on assessing “cardiometabolic risk (CMR)” or “global cardiometabolic risk” considers the factors that go beyond the traditional risk factors. In 2009, the Canadian Cardiometabolic Risk Working Group suggested that CMR represents the comprehensive catalogue of factors related to CVD and Type 2 diabetes. Therefore, in evaluating CMR, both MetS and 10-year risk of CVD are considered. The calculation of FRS followed by the evaluation of the presence or the absence of MetS helps identify individuals whose risk might be underestimated. Therefore, in order to evaluate CMR, both the risk factors of MetS and the risk factors used to calculate 10-year risk of CVD are considered. This novel approach, CMR, has been used to identify the risk of CVD at the individual level. Hypertension is a potent and modifiable CVD risk factor. The relationship between BP and CVD risk is linear, consistent, and independent of other risk factors. For instance, the probability of myocardial infarction, heart failure, chronic kidney disease, and stroke rises in step with BP. From a start point of 115/75 mmHg, CVD risk doubles for each 20 mmHg rise in systolic BP (SBP) and each 10 mmHg rise in diastolic BP. Hypertension-related CVD risk also escalates in the presence of other risk factors.

  • Track 1-1 Complications associated to diabetes and hypertension
  • Track 2-2 Evaluation and treatment of hypertension

Related Conference of Cardiology